close

Agreements

Date: 2018-08-02

Type of information: Nomination

Compound: US president and CEO

Company: Atlantic Healthcare (UK)

Therapeutic area: Inflammatory diseases - Gastrointestinal diseases

Type agreement: nomination

Action mechanism:

Disease:

Details:

  • • On August 2, 2018, Atlantic Healthcare  has appointed John Temperato as U.S. President and Chief Operating Officer, to lead the commercialisation programme of alicaforsen in the U.S.. Atlantic Healthcare is developing alicaforsen for the treatment of inflammatory bowel disease (IBD). Results of the fully-funded Phase 3 trial for alicaforsen enema in the treatment of orphan-designated IBD pouchitis are expected in Q1 2019. Subject to positive results from the trial and subsequent regulatory approval, Atlantic Healthcare will commercialise alicaforsen enema as the first and only approved treatment for pouchitis. Work is also ongoing to develop the pipeline for alicaforsen in additional indications, including distinct and novel tablet formulations to treat Crohn’s disease and ulcerative colitis (UC).
  • John Temperato joins Atlantic Healthcare from Melinta Therapeutics, where he was President and Chief Operating Officer / Chief Commercial Officer responsible for the commercialisation strategy and building the Company's product portfolio. Prior to Melinta, he headed sales and marketing at Salix Pharmaceuticals (now part of Valeant Pharmaceuticals, where he successfully launched numerous products, helping to grow revenue from $119 million in 2004 to $2 billion in 2015. John has also held positions at Celltech Pharmaceuticals, Medeva Pharmaceuticals and Adams Laboratories.
 

Financial terms:

Latest news:

Is general: Yes